EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal
EnGeneIC, an Australian clinical stage biotechnology company, has developed therapeutics for end stage patients with low survival cancers based on its revolutionary and world first EDV™ nanocell cyto-immunotherapy platform (EDV; EnGeneIC Dream Vector).
- EnGeneIC, an Australian clinical stage biotechnology company, has developed therapeutics for end stage patients with low survival cancers based on its revolutionary and world first EDV™ nanocell cyto-immunotherapy platform (EDV; EnGeneIC Dream Vector).
- More recently, the company discovered that the same EDV nanocell can deliver viral antigens, resulting in its novel COVID-EDV vaccine.
- EnGeneIC is currently conducting trials of its groundbreaking vaccine in Sydney and Melbourne and has vaccinated 80 volunteers.
- Many of these people are too stressed and concerned about the consequences of getting COVID – we strongly believe that we can help.